DOI:
10.1055/s-00000105
Zentralblatt für Gynäkologie
LinksClose Window
References
Seidman A, Berry D, Cirrincione C. et al.
CALGB 9840: Phase III study of weekly (w) paclitaxel via 1-hour (h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER-2 positive metastatic breast cancer and randomized for T in HER-2 normal MBC (abstr 512).
Proc Am Soc Clin Oncol 2004; 22: 6 s-6 s
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.